 |
 Video: What is a Stock Split?
|
|
|
| Enzon Pharmaceuticals receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron®, Sylatron®, Macugen® and CIMZIA®. PegIntron® is used for the treatment of chronic hepatitis C. Sylatron® is used for the treatment of melanoma. Macugen® is used for the treatment of neovascular (wet) age-related macular degeneration. CIMZIA® is used for the treatment of Crohn's disease and rheumatoid arthritis. Co. has no clinical operations and limited corporate operations. According to our ENZN split history records, ENZN has had 1 split. | |
|
ENZN (ENZN) has 1 split in our ENZN split history database. The split for ENZN took place on September 29, 2017.
Looking at the ENZN split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ENZN shares, starting with a $10,000 purchase of ENZN, presented on a split-history-adjusted basis factoring in the complete ENZN split history.
Growth of $10,000.00
With Dividends Reinvested
|
| Start date: |
02/12/2015 |
|
| End date: |
02/10/2025 |
|
| Start price/share: |
$0.99 |
|
| End price/share: |
$0.17 |
|
| Starting shares: |
10,101.01 |
|
| Ending shares: |
83,562.68 |
|
| Dividends reinvested/share: |
$1.23 |
|
| Total return: |
42.06% |
|
| Average Annual Total Return: |
3.57% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$14,203.05 |
|
| Years: |
10.00 |
|
| |
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/12/2015 |
|
| End date: |
02/10/2025 |
|
| Start price/share: |
$0.99 |
|
| End price/share: |
$0.17 |
|
| Dividends collected/share: |
$1.23 |
|
| Total return: |
41.41% |
|
| Average Annual Total Return: |
3.52% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$14,134.61 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 09/29/2017 | 1 for 1 |
|
|
Free ENZN Email Alerts:
